BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36265326)

  • 1. Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
    Aldabergenov D; Reynolds L; Scott J; Kelleher MJ; Strang J; Copeland CS; Kalk NJ
    Int J Drug Policy; 2022 Dec; 110():103877. PubMed ID: 36265326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
    Lehmann K; Kuhn S; Schulte B; Verthein U
    Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.
    Durand L; Boland F; Harnedy N; Delargy Í; Scully M; Bourke M; Ebbitt W; Otero Vázquez M; Keenan E; Cousins G
    J Subst Use Addict Treat; 2023 Jun; 149():209029. PubMed ID: 37003538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
    Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
    Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
    Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
    Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
    Hallowell BD; Weidele HR; Daly M; Chambers LC; Scagos RP; Gargano L; McDonald J
    Am J Public Health; 2021 Sep; 111(9):1600-1603. PubMed ID: 34410818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic.
    Lee K; Zhao Y; Merali T; Fraser C; Kozicky JM; Mormont MC; Conway B
    J Addict Med; 2023 Nov-Dec 01; 17(6):e374-e381. PubMed ID: 37934531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007.
    Zamparutti G; Schifano F; Corkery JM; Oyefeso A; Ghodse AH
    Br J Clin Pharmacol; 2011 Aug; 72(2):330-7. PubMed ID: 21235617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.